Dako to Collaborate With Pfizer on Companion Diagnostics

Dako to Collaborate With Pfizer on Companion Diagnostics 
GLOSTRUP, DENMARK -- (Marketwire) -- 02/12/13 --  Dako, an Agilent
Technologies company, announced today it has entered into a
collaboration agreement with Pfizer in the field of companion
The agreement constitutes a legal framework for various collaboration
projects between the two companies, covering research, development
and commercialization as well as advisory services. 
"We are extremely excited to partner with Pfizer, a company with such
a global presence and reputation for market leadership," said Lars
Holmkvist, CEO of Dako and senior vice president, Agilent. "This
collaboration is testimony to the level of expertise and service Dako
is committed to delivering to our partners in companion diagnostics." 
Companion diagnostics are seen as the cornerstones of precision
medicine. They provide a way to improve patient care and reduce
health-care costs by matching specific therapies to the individuals
most likely to benefit from them, since all patients do not respond
in the same way. 
"This partnership with Dako will support Pfizer's companion
diagnostics efforts, an important component of our growing Precision
Medicine capabilities," said John Hubbard, senior vice president,
Development Operations at Pfizer. "Precision Medicine R&D is designed
to advance more targeted therapies for patients, improve efficacy,
safety and success rates, and expedite development."  
Financial terms of the agreement were not disclosed. 
Today's news follows an earlier announcement from Dako introducing a
master framework agreement between Dako and Eli Lilly and Company,
which focuses on developing novel companion diagnostics for Eli
Lilly's oncology pipeline. 
About Dako - An Agilent Technologies Company
 Dako is relentless in
its commitment to fighting cancer together with customers and
strategic partners -- because patients' lives depend on companies
continuing to bring scientific advancement to the diagnostic and
therapeutic fields. 
Dako, based in Denmark, is a global leader in tissue-based cancer
diagnostics. Hospital and research laboratories worldwide use Dako's
reagents, instruments, software and expertise to make accurate
diagnoses and determine the most effective treatment for c
patients. Dako, with 1,200 employees, operates in more than 100
countries. Dako became part of Agilent Technologies on June 21, 2012.
Information about Dako is available at www.dako.com.  
About Agilent Technologies
 Agilent Technologies Inc. (NYSE: A) is
the world's premier measurement company and a technology leader in
chemical analysis, life sciences, diagnostics, electronics and
communications. The company's 20,500 employees serve customers in
more than 100 countries. Agilent had revenues of $6.9 billion in
fiscal 2012. Information about Agilent is available at
Maia Fredtoft Sochting 
+45 25 46 10 83
Dako Denmark A/S
Press spacebar to pause and continue. Press esc to stop.